to your health

Naming drug trials is an artform.

Naming drug trials is an artform. Here’s the latest result from Lilly’s retatrutide. “In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half […]

under the microscope

Lithium hypothesis of obesity.

I had read bits and pieces of this before, and it’s quite interesting. This is a thorough recap of the investigation into the hypothesis that lithium contamination is a major driver of obesity. “All this seems like pretty strong evidence […]

to your health

A hard thing about weight loss.

“But a new study has found that it may not be a lack of willpower, but a lack of dopamine signaling in response to nutrients – something more prevalent in adults with obesity – that encourages behaviors like high-sugar food […]

to your health

The economics of the new (effective) weight loss drugs.

Semaglutides came on the scene after last year’s FDA approval. “Until now, doctors didn’t really use medication to treat obesity; the drugs either didn’t work or had too many side effects. … Semaglutide marks the start of a new generation of […]